Allergies: nothing to sneeze at

The continuing rise in the prevalence of allergic diseases, such as asthma, allergic rhinitis and eczema, will place considerable strain on the NHS in the UK. Insufficient numbers of allergy specialists and inadequate allergy training in medical schools will severely restrict access to disease modifying treatments like immune therapy.<BR />

Published By Datamonitor

Altana considers divesting pharma business

Following disappointing trial results in its respiratory pipeline, a failure to secure the US approval of Alvesco, and the breakdown of its collaboration with Pfizer over Daxas, all eyes are on Altana as rumors suggest it is considering selling its drugs unit. As yet, Altana has neither confirmed nor denied the rumors, which follow a disappointing year for the company's pharmaceutical unit.

Published By Datamonitor

Altana: blockbuster potential for Daxas

Altana's [ALT.F] move to file for European marketing approval of Daxas makes the company the first in line to market a phosphodiesetrase-4 inhibitor for the treatment of asthma and COPD. Pfizer's marketing power will ensure that the drug reaches its full potential, and that could mean blockbuster status.

Published By Datamonitor

Asthma and eczema: gene discovery could be the missing link

University of Dundee researchers have discovered a new gene that, when mutated, causes eczema and may be associated with asthma. An estimated 10% of the European population carries this mutation, sometimes leading to severe, uncontrolled disease requiring specialist treatment. However, while the discovery holds promise for new treatments for these patients, these drugs are still a long way off.

Published By Datamonitor

Asthma treatments: UK favors generics

Published By Datamonitor

Asthma treatments: UK favors generics

Published By Datamonitor

Asthma/COPD innovation scarce among top pharmaceutical companies

Many asthma and chronic obstructive pulmonary disease patients are now being treated with inhaled corticosteroid/long-acting beta2-agonist fixed-dose combinations, a lifecycle management strategy generating high sales from a relatively low investment. However, the lack of truly novel drug targets means that other unmet needs in asthma and COPD are being overlooked by the leading players.

Published By Datamonitor

Asthma: bronchodilator treatments are the clear favorite in the UK

Published By Datamonitor

Asthma: new treatments still needed

Published By Datamonitor

Asthma: prevalence to increase worldwide

Published By Datamonitor